甲强龙联合低分子肝素治疗原发性肾病综合征的临床研究
|
摘要
目的探究在原发性肾病综合征治疗中,应用注射用甲泼尼龙琥珀酸钠(商品名:甲强龙)联合低分子肝素的效果。方法 60例原发性肾病综合征患者作为研究对象,随机分为观察组(给予甲强龙+低分子肝素治疗)和对照组(给予常规治疗),各30例。治疗后比较两组24 h尿蛋白、活化部分凝血活酶时间(APTT)、血浆凝血酶原时间(PT)水平,尿量增加时间,并发症发生率。结果治疗后,两组患者的24 h尿蛋白水平均较本组治疗前降低, PT、APTT水平均较本组治疗前升高,且观察组24 h尿蛋白、PT、APTT水平均优于对照组,差异均具有统计学意义(t=2.716、7.121、3.934, P<0.05)。观察组患者尿量增加时间为(7.36±1.23)d,对照组患者尿量增加时间为(9.29±1.16)d,观察组患者尿量增加时间早于对照组,差异具有统计学意义(t=6.252, P<0.05)。观察组并发症发生率为40.00%,低于对照组的70.00%,差异具有统计学意义(P<0.05)。结论将甲强龙+低分子肝素联合应用于原发性肾病综合征治疗中,可获得良好效果,具有推广价值。
Objective To investigate the effect of methylprednisolone sodium succinate for injection(trade name: methylprednisolone) combined with low molecular weight heparin in the treatment of primary nephrotic syndrome. Methods A total of 60 patients with primary nephrotic syndrome as study subjects were randomly divided into observation group(receiving methylprednisolone+low molecular weight heparin) and control group(receiving conventional therapy), with 30 cases in each group. Comparison were made on 24 h urinary protein, activated partial thromboplastin time(APTT), plasma prothrombin time(PT) level, urine volume increase time,complication rate after treatment between the two groups. Results After treatment, both groups had lower 24 h urinary protein than those before treatment, and higher PT and APTT than those before treatment. The observation group had better 24 h urinary protein, PT and APTT than the control group, and their difference was statistically significant(t=2.716, 7.121, 3.934, P<0.05). The observation group had urine volume increase time as(7.36± 1.23) d, which was(9.29±1.16) d in the control group. The observation group had early urine volume increase time than the control group, and the difference was statistically significant(t=6.252, P<0.05). The observation group had lower incidence of complications as 40.00% than 70.00% in the control group, and the difference was statistically significant(P<0.05). Conclusion The combination of methylprednisolone and low molecular weight heparin in the treatment of primary nephrotic syndrome can achieve good effect and has the value of promotion.Key words
Objective To investigate the effect of methylprednisolone sodium succinate for injection(trade name: methylprednisolone) combined with low molecular weight heparin in the treatment of primary nephrotic syndrome. Methods A total of 60 patients with primary nephrotic syndrome as study subjects were randomly divided into observation group(receiving methylprednisolone+low molecular weight heparin) and control group(receiving conventional therapy), with 30 cases in each group. Comparison were made on 24 h urinary protein, activated partial thromboplastin time(APTT), plasma prothrombin time(PT) level, urine volume increase time,complication rate after treatment between the two groups. Results After treatment, both groups had lower 24 h urinary protein than those before treatment, and higher PT and APTT than those before treatment. The observation group had better 24 h urinary protein, PT and APTT than the control group, and their difference was statistically significant(t=2.716, 7.121, 3.934, P<0.05). The observation group had urine volume increase time as(7.36± 1.23) d, which was(9.29±1.16) d in the control group. The observation group had early urine volume increase time than the control group, and the difference was statistically significant(t=6.252, P<0.05). The observation group had lower incidence of complications as 40.00% than 70.00% in the control group, and the difference was statistically significant(P<0.05). Conclusion The combination of methylprednisolone and low molecular weight heparin in the treatment of primary nephrotic syndrome can achieve good effect and has the value of promotion.Key words
引文
[1]陈荣芳,刘晓燕.低分子肝素钠辅助治疗58例原发性肾病综合征的临床效果观察.临床医学研究与实践, 2016, 1(2):35.
[2]左富凤.百令胶囊联合低分子肝素治疗儿童原发性肾病综合征疗效观察.临床研究, 2016, 24(12):77-78.
[3]Hopps SA, Borders EB, Hagemann TM. Prophylaxis and treatment recommendations for sinusoidal obstruction syndrome in adult and pediatric patients undergoing hematopoietic stem cell transplant:a review of the literature. Journal of Oncology Pharmacy Practice Official Publication of the International Society of Oncology Pharmacy Practitioners, 2016, 22(3):496.
[4]王海文.低分子肝素钙联合肾炎康复片治疗原发性肾病综合征的临床分析.大家健康(学术版), 2016, 10(6):13-15.
[5]胡姬婷.百令胶囊联合应用低分子肝素治疗儿童原发性肾病综合征的临床疗效分析.中国实用医药, 2016, 11(27):172-173.
[6]白雪.辛伐他汀与低分子肝素联合用药方案治疗肾病综合征的临床疗效研究.中国医药指南, 2016, 14(35):31-32.
[7]张桂月,王凤君,关美玉.低分子肝素钙联合肾炎康复片对原发性肾病综合征的治疗效果观察.当代医学, 2016, 22(29):150-151.
[8]张艳丽,李平.黄芪联合低分子肝素对老年原发性肾病综合征患者免疫功能的影响.中华保健医学杂志, 2017, 19(6):496-498.
[9]郭丽敏.低分子肝素联合卡托普利治疗儿童肾病综合征的效果研究.临床医药文献电子杂志, 2017, 4(36):7081.
[10]冯清胜,李春焕.低分子肝素联合泼尼松在小儿肾病综合征治疗中的应用价值探究.中国卫生标准管理, 2016, 7(5):69-70.
[11]廖冰,杨帆,蒋东波,等.甲强龙联合低分子肝素治疗原发性肾病综合征临床分析.四川医学, 2014(9):1168-1170.
[2]左富凤.百令胶囊联合低分子肝素治疗儿童原发性肾病综合征疗效观察.临床研究, 2016, 24(12):77-78.
[3]Hopps SA, Borders EB, Hagemann TM. Prophylaxis and treatment recommendations for sinusoidal obstruction syndrome in adult and pediatric patients undergoing hematopoietic stem cell transplant:a review of the literature. Journal of Oncology Pharmacy Practice Official Publication of the International Society of Oncology Pharmacy Practitioners, 2016, 22(3):496.
[4]王海文.低分子肝素钙联合肾炎康复片治疗原发性肾病综合征的临床分析.大家健康(学术版), 2016, 10(6):13-15.
[5]胡姬婷.百令胶囊联合应用低分子肝素治疗儿童原发性肾病综合征的临床疗效分析.中国实用医药, 2016, 11(27):172-173.
[6]白雪.辛伐他汀与低分子肝素联合用药方案治疗肾病综合征的临床疗效研究.中国医药指南, 2016, 14(35):31-32.
[7]张桂月,王凤君,关美玉.低分子肝素钙联合肾炎康复片对原发性肾病综合征的治疗效果观察.当代医学, 2016, 22(29):150-151.
[8]张艳丽,李平.黄芪联合低分子肝素对老年原发性肾病综合征患者免疫功能的影响.中华保健医学杂志, 2017, 19(6):496-498.
[9]郭丽敏.低分子肝素联合卡托普利治疗儿童肾病综合征的效果研究.临床医药文献电子杂志, 2017, 4(36):7081.
[10]冯清胜,李春焕.低分子肝素联合泼尼松在小儿肾病综合征治疗中的应用价值探究.中国卫生标准管理, 2016, 7(5):69-70.
[11]廖冰,杨帆,蒋东波,等.甲强龙联合低分子肝素治疗原发性肾病综合征临床分析.四川医学, 2014(9):1168-1170.